banner add

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.

from NYT > Health https://ift.tt/NWShtOr
via IFTTT

No comments

Moderna’s Shift to Cancer Company Lifts Stock Up 177%

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else. from NYT > Health...

Theme images by PLAINVIEW. Powered by Blogger.